VIGMED GRANTED PATENT FOR ITS FIRST CLOSED SYSTEM IV CATHETERS

The Swedish Patent and Registration Office (PRV) has announced to Vigmed that it
intends to approve the Company’s patent application for their closed system,
needle protecting I.V. catheters.
The patent is Vigmed's first for a so-called “closed I.V. system”, and an
international patent application has been filed. A closed IV system reduces the
risk of infection in comparison to a conventional IV catheter.  This new patent
will take Vigmed and their safety products to an even higher level of safety and
patient security.

"This particular product patent is important as it gives the Company the rights
that will be applied to other future product types for closed systems - whether
specially designed for the Asian, European or American markets”, says Fredrik
Thorne Vigmed R&D Director.

Vigmed's product design is far more cost effective than the security products
for closed I.V. systems available in the market today. Products in the closed IV
system segment command greater premiums compared to standard IV systems.

Vigmed has filed more than 60 patents and patent applications internationally
which are based on 10 patent families. The company owns all its patents and
patent applications without any restrictions. The basic patents all have a
maximum validity period.

Vigmed’s strategy is to protect the Company's technology and products in all
geographical areas deemed to be of importance. Vigmed intends to expand its
patent portfolio continuously on both the offensive and defensive patent and
utility model rights.
For further information contact:

CEO, Finn Ketler 46 42 600 5311 or R&D Director, Fredrik Thörne 46 42 600 5312
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market unique needle-protected products.
Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20
employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm
(ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the
Company’s Certified Advisor.

Additional information such as company description, a video presentation and
risk factors can be found on Vigmed’s website: www.vigmed.com/investor